From: The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome
Gene/SNP | Genotype frequencies (IC 95%) | |||||
---|---|---|---|---|---|---|
Recurrence-free group | Recurrence group | |||||
CYP3A4*1B | AA | AG | GG | AA | AG | GG |
8/71 (0.113; 0.053–0.215) | 37/71 (0.521; 0.400–0.640) | 26/71 (0.366; 0.258–0.490) | 3/28 (0.107; 0.028–0.294) | 10/28 (0.357; 0.193–0.559) | 15/28 (0.536; 0.342–0.720) | |
ABCB1 3435C>T | CC | CT | TT | CC | CT | TT |
60/72* (0.833; 0.723–0.907) | 10/72* (0.077; 0.072–0.245) | 2/72* (0.028; 0.005–0.106) | 17/29* (0.586; 0.391–0.760) | 6/29* (0.207; 0.087–0.403) | 6/29* (0.207; 0.087–0.403) | |
CYP3A5*3 | AA | AG | GG | AA | AG | GG |
46/59 (0.780; 0.653–0.877) | 11/59 (0.186; 0.097–0.309) | 2/59 (0.034; 0.004–0.117) | 17/25 (0.680; 0.465–0.851) | 6/25 (0.240; 0.094–0.451) | 2/25 (0.080; 0.010–0.260) |